Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2017 May 22

PMID 28527709

Citations 85

Authors

Gabrielle Fredman

Ira Tabas

Affiliations

Soon will be listed here.

Abstract

Defective inflammation resolution is the underlying cause of prevalent chronic inflammatory diseases, such as arthritis, asthma, cancer, and neurodegenerative and cardiovascular diseases. Inflammation resolution is governed by several endogenous factors, including fatty acid-derived specialized proresolving mediators and proteins, such as annexin A1. Specifically, specialized proresolving mediators comprise a family of mediators that include arachidonic acid-derived lipoxins, omega-3 fatty acid eicosapentaenoic acid-derived resolvins, docosahexaenoic acid-derived resolvins, protectins, and maresins. Emerging evidence indicates that imbalances between specialized proresolving mediators and proinflammatory mediators are associated with several prevalent human diseases, including atherosclerosis. Mechanisms that drive this imbalance remain largely unknown and will be discussed in this review. Furthermore, the concept of dysregulated inflammation resolution in atherosclerosis has been known for several decades. Recently, there has been an explosion of new work with regard to the therapeutic application of proresolving ligands in experimental atherosclerosis. Therefore, this review will highlight recent advances in our understanding of how inflammation resolution may become defective in atherosclerosis and the potential for proresolving therapeutics in atherosclerosis. Last, we offer insight for future implications of the field.

Citing Articles

Phytochemical-mediated efferocytosis and autophagy in inflammation control.

Vafadar A, Tajbakhsh A, Hosseinpour-Soleimani F, Savardshtaki A, Hashempur M Cell Death Discov. 2024; 10(1):493.

PMID: 39695119 PMC: 11655565. DOI: 10.1038/s41420-024-02254-2.

Inflammation in atherosclerosis: pathophysiology and mechanisms.

Ajoolabady A, Pratico D, Lin L, Mantzoros C, Bahijri S, Tuomilehto J Cell Death Dis. 2024; 15(11):817.

PMID: 39528464 PMC: 11555284. DOI: 10.1038/s41419-024-07166-8.

Study on serum metabolomics characteristics of obese patients with erectile dysfunction.

Lin Y, Pan R, Deng R, Fang S, Yang H, Zhang X Medicine (Baltimore). 2024; 103(43):e40093.

PMID: 39470567 PMC: 11521011. DOI: 10.1097/MD.0000000000040093.

IL-1β Inhibition Partially Negates the Beneficial Effects of Diet-Induced Atherosclerosis Regression in Mice.

Karnewar S, Karnewar V, Deaton R, Shankman L, Benavente E, Williams C Arterioscler Thromb Vasc Biol. 2024; 44(6):1379-1392.

PMID: 38695167 PMC: 11111338. DOI: 10.1161/ATVBAHA.124.320800.

Atherosclerosis and the Bidirectional Relationship between Cancer and Cardiovascular Disease: From Bench to Bedside-Part 1.

Gallucci G, Turazza F, Inno A, Canale M, Silvestris N, Fari R Int J Mol Sci. 2024; 25(8).

PMID: 38673815 PMC: 11049833. DOI: 10.3390/ijms25084232.

References

Fredman G, Oh S, Ayilavarapu S, Hasturk H, Serhan C, Van Dyke T . Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1. PLoS One. 2011; 6(9):e24422. PMC: 3173372. DOI: 10.1371/journal.pone.0024422. View

Lance K, Chatterjee A, Wu B, Mottola G, Nuhn H, Lee P . Unidirectional and sustained delivery of the proresolving lipid mediator resolvin D1 from a biodegradable thin film device. J Biomed Mater Res A. 2016; 105(1):31-41. PMC: 5124518. DOI: 10.1002/jbm.a.35861. View

Chiang N, Fredman G, Backhed F, Oh S, Vickery T, Schmidt B . Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature. 2012; 484(7395):524-8. PMC: 3340015. DOI: 10.1038/nature11042. View

Back M, Bu D, Branstrom R, Sheikine Y, Yan Z, Hansson G . Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A. 2005; 102(48):17501-6. PMC: 1297663. DOI: 10.1073/pnas.0505845102. View

Michel O, Nagy A, Schroeven M, Duchateau J, Neve J, Fondu P . Dose-response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med. 1997; 156(4 Pt 1):1157-64. DOI: 10.1164/ajrccm.156.4.97-02002. View

Feinberg M, Moore K . MicroRNA Regulation of Atherosclerosis. Circ Res. 2016; 118(4):703-20. PMC: 4762069. DOI: 10.1161/CIRCRESAHA.115.306300. View

Fredman G, Van Dyke T, Serhan C . Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol. 2010; 30(10):2005-13. PMC: 2982748. DOI: 10.1161/ATVBAHA.110.209908. View

Tabas I . Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2009; 10(1):36-46. PMC: 2854623. DOI: 10.1038/nri2675. View

Arnardottir H, Dalli J, Colas R, Shinohara M, Serhan C . Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. J Immunol. 2014; 193(8):4235-44. PMC: 4185223. DOI: 10.4049/jimmunol.1401313. View

10.

Dufton N, Hannon R, Brancaleone V, Dalli J, Patel H, Gray M . Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol. 2010; 184(5):2611-2619. PMC: 4256430. DOI: 10.4049/jimmunol.0903526. View

11.

Cai B, Thorp E, Doran A, Subramanian M, Sansbury B, Lin C . MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc Natl Acad Sci U S A. 2016; 113(23):6526-31. PMC: 4988577. DOI: 10.1073/pnas.1524292113. View

12.

Aiello R, Bourassa P, Lindsey S, Weng W, Freeman A, Showell H . Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002; 22(3):443-9. DOI: 10.1161/hq0302.105593. View

13.

Levy B, Bonnans C, Silverman E, Palmer L, Marigowda G, Israel E . Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med. 2005; 172(7):824-30. PMC: 2718403. DOI: 10.1164/rccm.200410-1413OC. View

14.

Karunakaran D, Geoffrion M, Wei L, Gan W, Richards L, Shangari P . Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci Adv. 2016; 2(7):e1600224. PMC: 4985228. DOI: 10.1126/sciadv.1600224. View

15.

Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

16.

Heidt T, Sager H, Courties G, Dutta P, Iwamoto Y, Zaltsman A . Chronic variable stress activates hematopoietic stem cells. Nat Med. 2014; 20(7):754-758. PMC: 4087061. DOI: 10.1038/nm.3589. View

17.

Miyahara T, Runge S, Chatterjee A, Chen M, Mottola G, Fitzgerald J . D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 2013; 27(6):2220-32. PMC: 3659350. DOI: 10.1096/fj.12-225615. View

18.

Day R, Harbord M, Forbes A, Segal A . Cantharidin blisters: a technique for investigating leukocyte trafficking and cytokine production at sites of inflammation in humans. J Immunol Methods. 2001; 257(1-2):213-20. DOI: 10.1016/s0022-1759(01)00467-7. View

19.

Kusters D, Chatrou M, Willems B, De Saint-Hubert M, Bauwens M, van der Vorst E . Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR-/- Mice on Western Type Diet. PLoS One. 2015; 10(6):e0130484. PMC: 4475013. DOI: 10.1371/journal.pone.0130484. View

20.

Patel P, Shah R, Ferguson J, Reilly M . Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases. Arterioscler Thromb Vasc Biol. 2015; 35(3):525-34. PMC: 4344396. DOI: 10.1161/ATVBAHA.114.304455. View